Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at Â鶹ӳ» MD Anderson Cancer Center.
The findings, published today in The Lancet, support the use of momelotinib – a potent ACVR1/ALK2...
MD Anderson’s Jennifer Wargo receives TAMEST O’Donnell Award for pioneering microbiome research
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at Â鶹ӳ» MD Anderson Cancer Center, has received...